Cargando…
Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial
AIMS: Cardiovascular (CV) disease is a major cause of reduced life expectancy in type 1 diabetes (T1D). Intensive insulin therapy prevents CV complications but is constrained by hypoglycaemia and weight gain. Adjunct metformin reduces insulin dose requirement and stabilizes weight but there are no d...
Ejemplares similares
-
Cardiometabolic risk factors, peripheral arterial tonometry and metformin in adults with type 1 diabetes participating in the REducing with MetfOrmin Vascular Adverse Lesions trial
por: Chen, David, et al.
Publicado: (2023) -
MetfOrmin BenefIts Lower Extremities with Intermittent Claudication (MOBILE IC): randomized clinical trial protocol
por: Reitz, Katherine M., et al.
Publicado: (2023) -
Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study
por: Bell, Samira, et al.
Publicado: (2017) -
Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks?
por: Cleland, S. J., et al.
Publicado: (2013) -
Second-Generation Insulin Analogues – a Review of Recent Real-World Data and Forthcoming Head-to-Head Comparisons
por: Mauricio, Didac, et al.
Publicado: (2018)